Nanomedicine Market by Modality (Treatments and Diagnostics), Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, and Others), and Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Disorders, Neurological Diseases, Urological Diseases, Ophthalmological Diseases, Immunological Diseases, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Nanomedicine is a branch of medicine that uses tools and knowledge of nanotechnology for prevention and treatment of different diseases. Nanomedicines are multifunctional drugs with programmable properties that find applications in monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. These nanomedicines have the potential to revolutionize the current scenario of detection of disease, its treatment, and diagnosis methods. The global nanomedicine market accounted for $111,912 million in 2016, and is anticipated to reach $261,063 million by 2023, registering a CAGR of 12.6% from 2017 to 2023.
The global nanomedicine market is driven by emerging innovative technologies for drug delivery, advantages of nanomedicine in various healthcare applications, rise in government support and funding, and growth in need for safe and cost-effective therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are anticipated to provide numerous opportunities for the market growth.
The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. Based on indication, it is categoried into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopaedic disorders, immunological diseases, cardiovascular diseases, and others. On the basis of modality, it is bifurcated into treatments and diagnostics.
Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in the global market, owing to increase in presence of stronger players focussed on R&D activities and commercialization of nanomedicines in the region. In addition, this region leads in the number of nanotechnology patent applications resulting in higher demand in the market. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, owing to the rapid development of healthcare infrastructure and growth in health awareness among the middle-class population.
The key players operating in the global market have focused on expanding their presence in the nanomedicine sector. Moreover, new players moving into healthcare contribute by expanding expertise range, leveraging diversification, and augmenting scale by providing the necessary capital for the nanomedicine development.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global nanomedicine market and the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on product assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
By Application
Drug Delivery
Vaccines
Diagnostic Imaging
Regenerative Medicine
Implants
Others
By Modality
Diagnostics
Treatments
By Indication
Oncological Diseases
Infectious Diseases
Cardiovascular Diseases
Orthopedic Disorders
Neurological Diseases
Urological Diseases
Ophthalmological Diseases
Immunological Diseases
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Saudi Arabia
South Africa
Rest of LAMEA
KEY PLAYERS PROFILED
Abbott Laboratories
CombiMatrix Corporation
General electric Company
Sigma-Tau Pharmaceuticals, Inc.
Johnson & Johnson
Mallinckrodt plc.
Merck & Company, Inc.
Nanosphere, Inc.
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
The other players in the value chain include (profiles not included in the report)
Celgene Corporation
UCB (Union Chimique Belge) S.A.
AMAG Pharmaceuticals
Nanospectra Biosciences, Inc.
Arrowhead Pharmaceuticals, Inc.
Leadiant Biosciences, Inc.
Epeius Biotechnologies Corporation
Gilead
Cytimmune Sciences, Inc.
NanoCarrier
LTT BioPharma
Mebiopharm
The global nanomedicine market is driven by emerging innovative technologies for drug delivery, advantages of nanomedicine in various healthcare applications, rise in government support and funding, and growth in need for safe and cost-effective therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are anticipated to provide numerous opportunities for the market growth.
The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. Based on indication, it is categoried into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopaedic disorders, immunological diseases, cardiovascular diseases, and others. On the basis of modality, it is bifurcated into treatments and diagnostics.
Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in the global market, owing to increase in presence of stronger players focussed on R&D activities and commercialization of nanomedicines in the region. In addition, this region leads in the number of nanotechnology patent applications resulting in higher demand in the market. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, owing to the rapid development of healthcare infrastructure and growth in health awareness among the middle-class population.
The key players operating in the global market have focused on expanding their presence in the nanomedicine sector. Moreover, new players moving into healthcare contribute by expanding expertise range, leveraging diversification, and augmenting scale by providing the necessary capital for the nanomedicine development.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global nanomedicine market and the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on product assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
By Application
Drug Delivery
Vaccines
Diagnostic Imaging
Regenerative Medicine
Implants
Others
By Modality
Diagnostics
Treatments
By Indication
Oncological Diseases
Infectious Diseases
Cardiovascular Diseases
Orthopedic Disorders
Neurological Diseases
Urological Diseases
Ophthalmological Diseases
Immunological Diseases
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Saudi Arabia
South Africa
Rest of LAMEA
KEY PLAYERS PROFILED
Abbott Laboratories
CombiMatrix Corporation
General electric Company
Sigma-Tau Pharmaceuticals, Inc.
Johnson & Johnson
Mallinckrodt plc.
Merck & Company, Inc.
Nanosphere, Inc.
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
The other players in the value chain include (profiles not included in the report)
Celgene Corporation
UCB (Union Chimique Belge) S.A.
AMAG Pharmaceuticals
Nanospectra Biosciences, Inc.
Arrowhead Pharmaceuticals, Inc.
Leadiant Biosciences, Inc.
Epeius Biotechnologies Corporation
Gilead
Cytimmune Sciences, Inc.
NanoCarrier
LTT BioPharma
Mebiopharm
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO
3.4.1. FDA
3.4.2. Health Canada
3.4.3. CE Mark
3.4.4. Ministry of Health, Labor, and Welfare (MHLW)
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Emerging innovative technologies for drug delivery
3.6.1.2. Increase adoption of nanomedicine across varied applications
3.6.1.3. Rising government support and funding
3.6.1.4. Growing need of therapies that have fewer side effects and are cost effective
3.6.2. Restraints
3.6.2.1. Long approval process
3.6.2.2. Risks associated with nanomedicine (environmental impacts)
3.6.3. Opportunities
3.6.3.1. Growth of healthcare facilities in emerging economies
CHAPTER 4 NANOMEDICINE MARKET, BY APPLICATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. VACCINES
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. REGENERATIVE MEDICINE
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. DIAGNOSTIC IMAGING
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. DRUG DELIVERY
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. IMPLANTS
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
4.7. OTHERS
4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast
CHAPTER 5 NANOMEDICINE MARKET, BY INDICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ONCOLOGICAL DISEASES
5.2.1. Market size and forecast
5.3. INFECTIOUS DISEASES
5.3.1. Market size and forecast
5.4. CARDIOVASCULAR DISEASES
5.4.1. Market size and forecast
5.5. ORTHOPEDIC DISORDERS
5.5.1. Market size and forecast
5.6. NEUROLOGICAL DISORDERS
5.6.1. Market size and forecast
5.7. UROLOGICAL DISEASES
5.7.1. Market size and forecast
5.8. OPHTHALMOLOGICAL DISEASES
5.8.1. Market size and forecast
5.9. IMMUNOLOGICAL DISEASES
5.9.1. Market size and forecast
5.10. OTHERS
5.10.1. Market size and forecast
CHAPTER 6 NANOMEDICINE MARKET, BY MODALITY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. TREATMENTS
6.2.1. Market size and forecast
6.3. DIAGNOSTICS
6.3.1. Market size and forecast
CHAPTER 7 NANOMEDICINE MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Mexico market size and forecast
7.2.3.3. Canada market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.3.1. Germany market size and forecast
7.3.3.2. UK market size and forecast
7.3.3.3. France market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.3.1. India market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Japan market size and forecast
7.4.3.4. Australia market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.3.1. Brazil market size and forecast
7.5.3.2. South Africa market size and forecast
7.5.3.3. South Arabia market size and forecast
7.5.3.4. Argentina market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments
8.2. COMBIMATRIX CORPORATION
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments
8.3. GENERAL ELECTRIC COMPANY
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. SIGMA-TAU PHARMACEUTICALS, INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Key strategic moves and developments
8.5. JOHNSON & JOHNSON PRIVATE LIMITED
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments
8.6. MALLINCKRODT PLC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments
8.7. MERCK & COMPANY, INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. LUMINEX CORPORATION
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments
8.9. PFIZER, INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO
3.4.1. FDA
3.4.2. Health Canada
3.4.3. CE Mark
3.4.4. Ministry of Health, Labor, and Welfare (MHLW)
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Emerging innovative technologies for drug delivery
3.6.1.2. Increase adoption of nanomedicine across varied applications
3.6.1.3. Rising government support and funding
3.6.1.4. Growing need of therapies that have fewer side effects and are cost effective
3.6.2. Restraints
3.6.2.1. Long approval process
3.6.2.2. Risks associated with nanomedicine (environmental impacts)
3.6.3. Opportunities
3.6.3.1. Growth of healthcare facilities in emerging economies
CHAPTER 4 NANOMEDICINE MARKET, BY APPLICATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. VACCINES
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. REGENERATIVE MEDICINE
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. DIAGNOSTIC IMAGING
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. DRUG DELIVERY
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. IMPLANTS
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
4.7. OTHERS
4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast
CHAPTER 5 NANOMEDICINE MARKET, BY INDICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ONCOLOGICAL DISEASES
5.2.1. Market size and forecast
5.3. INFECTIOUS DISEASES
5.3.1. Market size and forecast
5.4. CARDIOVASCULAR DISEASES
5.4.1. Market size and forecast
5.5. ORTHOPEDIC DISORDERS
5.5.1. Market size and forecast
5.6. NEUROLOGICAL DISORDERS
5.6.1. Market size and forecast
5.7. UROLOGICAL DISEASES
5.7.1. Market size and forecast
5.8. OPHTHALMOLOGICAL DISEASES
5.8.1. Market size and forecast
5.9. IMMUNOLOGICAL DISEASES
5.9.1. Market size and forecast
5.10. OTHERS
5.10.1. Market size and forecast
CHAPTER 6 NANOMEDICINE MARKET, BY MODALITY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. TREATMENTS
6.2.1. Market size and forecast
6.3. DIAGNOSTICS
6.3.1. Market size and forecast
CHAPTER 7 NANOMEDICINE MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Mexico market size and forecast
7.2.3.3. Canada market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.3.1. Germany market size and forecast
7.3.3.2. UK market size and forecast
7.3.3.3. France market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.3.1. India market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Japan market size and forecast
7.4.3.4. Australia market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.3.1. Brazil market size and forecast
7.5.3.2. South Africa market size and forecast
7.5.3.3. South Arabia market size and forecast
7.5.3.4. Argentina market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments
8.2. COMBIMATRIX CORPORATION
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments
8.3. GENERAL ELECTRIC COMPANY
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. SIGMA-TAU PHARMACEUTICALS, INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Key strategic moves and developments
8.5. JOHNSON & JOHNSON PRIVATE LIMITED
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments
8.6. MALLINCKRODT PLC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments
8.7. MERCK & COMPANY, INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. LUMINEX CORPORATION
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments
8.9. PFIZER, INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 2. GLOBAL NANOMEDICINE MARKET FOR VACCINES APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL NANOMEDICINE MARKET FOR REGENERATIVE MEDICINE APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTIC IMAGING APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 5. GLOBAL NANOMEDICINE MARKET FOR DRUG DELIVERY APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 6. GLOBAL NANOMEDICINE MARKET FOR IMPLANTS APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL NANOMEDICINE MARKET FOR OTHERS APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL NANOMEDICINE MARKET FOR ONCOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL NANOMEDICINE MARKET FOR INFECTIOUS DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GLOBAL NANOMEDICINE MARKET FOR CARDIOVASCULAR DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GLOBAL NANOMEDICINE MARKET FOR ORTHOPEDIC DIORDERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL NANOMEDICINE MARKET FOR NEUROLOGICAL DISORDERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL NANOMEDICINE MARKET FOR UROLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL NANOMEDICINE MARKET FOR OPHTHALMOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL NANOMEDICINE MARKET FOR IMMUNOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL NANOMEDICINE MARKET FOR OTHERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 19. GLOBAL NANOMEDICINE MARKET FOR TREATMENT MODALITY, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTICS MODALITY, BY REGION, 2016-2023 ($MILLION)
TABLE 21. NANOMEDICINE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 26. EUROPE NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. EUROPE NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. EUROPE NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 29. EUROPE NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 30. ASIA-PACIFIC NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 34. LAMEA NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 35. LAMEA NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. LAMEA NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 37. LAMEA NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 38. ABBOTT: COMPANY SNAPSHOT
TABLE 39. ABBOTT: OPERATING SEGMENTS
TABLE 40. COMBIMATRIX: COMPANY SNAPSHOT
TABLE 41. COMBIMATRIX: OPERATING SEGMENTS
TABLE 42. GE: COMPANY SNAPSHOT
TABLE 43. GE: OPERATING SEGMENTS
TABLE 44. SIGMA: COMPANY SNAPSHOT
TABLE 45. SIGMA: OPERATING SEGMENTS
TABLE 46. J&J: COMPANY SNAPSHOT
TABLE 47. J&J: OPERATING SEGMENTS
TABLE 48. MALLINCKRODT: COMPANY SNAPSHOT
TABLE 49. MALLINCKRODT: OPERATING SEGMENTS
TABLE 50. MERCK: COMPANY SNAPSHOT
TABLE 51. MERCK: OPERATING SEGMENTS
TABLE 52. LUMINEX: COMPANY SNAPSHOT
TABLE 53. LUMINEX: OPERATING SEGMENTS
TABLE 54. PFIZER: COMPANY SNAPSHOT
TABLE 55. PFIZER: OPERATING SEGMENTS
TABLE 56. TEVA: COMPANY SNAPSHOT
TABLE 57. TEVA: OPERATING SEGMENTS
TABLE 1. GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 2. GLOBAL NANOMEDICINE MARKET FOR VACCINES APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL NANOMEDICINE MARKET FOR REGENERATIVE MEDICINE APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTIC IMAGING APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 5. GLOBAL NANOMEDICINE MARKET FOR DRUG DELIVERY APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 6. GLOBAL NANOMEDICINE MARKET FOR IMPLANTS APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL NANOMEDICINE MARKET FOR OTHERS APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL NANOMEDICINE MARKET FOR ONCOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL NANOMEDICINE MARKET FOR INFECTIOUS DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GLOBAL NANOMEDICINE MARKET FOR CARDIOVASCULAR DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GLOBAL NANOMEDICINE MARKET FOR ORTHOPEDIC DIORDERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL NANOMEDICINE MARKET FOR NEUROLOGICAL DISORDERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL NANOMEDICINE MARKET FOR UROLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL NANOMEDICINE MARKET FOR OPHTHALMOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL NANOMEDICINE MARKET FOR IMMUNOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL NANOMEDICINE MARKET FOR OTHERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 19. GLOBAL NANOMEDICINE MARKET FOR TREATMENT MODALITY, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTICS MODALITY, BY REGION, 2016-2023 ($MILLION)
TABLE 21. NANOMEDICINE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 26. EUROPE NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. EUROPE NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. EUROPE NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 29. EUROPE NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 30. ASIA-PACIFIC NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 34. LAMEA NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 35. LAMEA NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. LAMEA NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 37. LAMEA NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 38. ABBOTT: COMPANY SNAPSHOT
TABLE 39. ABBOTT: OPERATING SEGMENTS
TABLE 40. COMBIMATRIX: COMPANY SNAPSHOT
TABLE 41. COMBIMATRIX: OPERATING SEGMENTS
TABLE 42. GE: COMPANY SNAPSHOT
TABLE 43. GE: OPERATING SEGMENTS
TABLE 44. SIGMA: COMPANY SNAPSHOT
TABLE 45. SIGMA: OPERATING SEGMENTS
TABLE 46. J&J: COMPANY SNAPSHOT
TABLE 47. J&J: OPERATING SEGMENTS
TABLE 48. MALLINCKRODT: COMPANY SNAPSHOT
TABLE 49. MALLINCKRODT: OPERATING SEGMENTS
TABLE 50. MERCK: COMPANY SNAPSHOT
TABLE 51. MERCK: OPERATING SEGMENTS
TABLE 52. LUMINEX: COMPANY SNAPSHOT
TABLE 53. LUMINEX: OPERATING SEGMENTS
TABLE 54. PFIZER: COMPANY SNAPSHOT
TABLE 55. PFIZER: OPERATING SEGMENTS
TABLE 56. TEVA: COMPANY SNAPSHOT
TABLE 57. TEVA: OPERATING SEGMENTS
LIST OF FIGURES
FIGURE 1. SNAPSHOT GLOBAL NANOMEDICINE MARKET, 2016-2023
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL NANOMEDICINE MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOTAL NUMBER OF STRATEGIES: GLOBAL DISPOSABLE MEDICAL SENSORS MARKET
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. MARKET SHARE ANALYSIS: NANOMEDICINE MARKET, 2016
FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL NANOMEDICINE MARKET
FIGURE 13. GLOBAL NANOMEDICINE MARKET, BY APPLICATION
FIGURE 14. NANOMEDICINE MARKET, BY INDICATION
FIGURE 15. NANOMEDICINE MARKET, BY REGION
FIGURE 16. NORTH AMERICA NANOMEDICINE MARKET, 2016-2023
FIGURE 17. U.S. NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 18. MEXICO NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 19. CANADA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 20. GERMANY NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 21. UK NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 22. FRANCE NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 23. ITALY NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 24. SPAIN NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 25. REST OF EUROPE NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 26. INDIA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 27. CHINA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 28. JAPAN NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 29. AUSTRALIA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 30. REST OF ASIA-PACIFIC NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 31. BRAZIL NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 32. SOUTH AFRICA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 33. SOUTH ARABIA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 34. ARGENTINA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 35. REST OF LAMEA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 36. ABBOTT: NET SALES, 2014-2017 ($MILLION)
FIGURE 37. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 38. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 39. COMBIMATRIX: NET SALES, 2014-2017 ($MILLION)
FIGURE 40. COMBIMATRIX: REVENUE BY SEGMENT, 2016 (%)
FIGURE 41. COMBIMATRIX: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 42. GE: NET SALES, 2014-2017 ($MILLION)
FIGURE 43. GE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 44. GE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 45. J&J: NET SALES, 2014-2017 ($MILLION)
FIGURE 46. J&J: REVENUE BY SEGMENT, 2016 (%)
FIGURE 47. J&J: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 48. MALLINCKRODT: NET SALES, 2014-2017 ($MILLION)
FIGURE 49. MALLINCKRODT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 50. MALLINCKRODT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 51. MERCK: NET SALES, 2014-2017 ($MILLION)
FIGURE 52. MERCK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 53. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 54. LUMINEX: NET SALES, 2014-2017 ($MILLION)
FIGURE 55. LUMINEX: REVENUE BY SEGMENT, 2016 (%)
FIGURE 56. LUMINEX: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 57. PFIZER: NET SALES, 2014-2017 ($MILLION)
FIGURE 58. PFIZER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 59. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 60. TEVA: NET SALES, 2014-2017 ($MILLION)
FIGURE 61. TEVA: REVENUE BY SEGMENT, 2016 (%)
FIGURE 62. TEVA: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 1. SNAPSHOT GLOBAL NANOMEDICINE MARKET, 2016-2023
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL NANOMEDICINE MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOTAL NUMBER OF STRATEGIES: GLOBAL DISPOSABLE MEDICAL SENSORS MARKET
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. MARKET SHARE ANALYSIS: NANOMEDICINE MARKET, 2016
FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL NANOMEDICINE MARKET
FIGURE 13. GLOBAL NANOMEDICINE MARKET, BY APPLICATION
FIGURE 14. NANOMEDICINE MARKET, BY INDICATION
FIGURE 15. NANOMEDICINE MARKET, BY REGION
FIGURE 16. NORTH AMERICA NANOMEDICINE MARKET, 2016-2023
FIGURE 17. U.S. NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 18. MEXICO NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 19. CANADA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 20. GERMANY NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 21. UK NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 22. FRANCE NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 23. ITALY NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 24. SPAIN NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 25. REST OF EUROPE NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 26. INDIA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 27. CHINA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 28. JAPAN NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 29. AUSTRALIA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 30. REST OF ASIA-PACIFIC NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 31. BRAZIL NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 32. SOUTH AFRICA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 33. SOUTH ARABIA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 34. ARGENTINA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 35. REST OF LAMEA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 36. ABBOTT: NET SALES, 2014-2017 ($MILLION)
FIGURE 37. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 38. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 39. COMBIMATRIX: NET SALES, 2014-2017 ($MILLION)
FIGURE 40. COMBIMATRIX: REVENUE BY SEGMENT, 2016 (%)
FIGURE 41. COMBIMATRIX: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 42. GE: NET SALES, 2014-2017 ($MILLION)
FIGURE 43. GE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 44. GE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 45. J&J: NET SALES, 2014-2017 ($MILLION)
FIGURE 46. J&J: REVENUE BY SEGMENT, 2016 (%)
FIGURE 47. J&J: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 48. MALLINCKRODT: NET SALES, 2014-2017 ($MILLION)
FIGURE 49. MALLINCKRODT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 50. MALLINCKRODT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 51. MERCK: NET SALES, 2014-2017 ($MILLION)
FIGURE 52. MERCK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 53. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 54. LUMINEX: NET SALES, 2014-2017 ($MILLION)
FIGURE 55. LUMINEX: REVENUE BY SEGMENT, 2016 (%)
FIGURE 56. LUMINEX: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 57. PFIZER: NET SALES, 2014-2017 ($MILLION)
FIGURE 58. PFIZER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 59. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 60. TEVA: NET SALES, 2014-2017 ($MILLION)
FIGURE 61. TEVA: REVENUE BY SEGMENT, 2016 (%)
FIGURE 62. TEVA: REVENUE BY GEOGRAPHY, 2016 (%)
